The final results of the AGITG ICECREAM trial were presented at this year’s ASCO meeting in Chicago on 3 June, 2017. Many AGITG members and international colleagues participated in this important study, one of the first prospective trials to limit accrual to pre-defined molecular subsets of colorectal cancer.
Professor Jeremy Shapiro (pictured above) lead author commented that “the results of this important trial will add 2 further pieces to the complex colorectal treatment jigsaw”
Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA. | 2017 ASCO Annual Meeting Abstracts
INTEGRATE II was also presented at ASCO in June in the progress session. Dr Katrin Sjoquist, INTEGRATE II Principal Investigator at St George Hospital (pictured above) commented:
“I was pleased to present the INTEGRATE II poster on behalf of the team at ASCO this year. The Trials In Progress session was a great opportunity to highlight this trial and we received overwhelmingly positive feedback”
Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).
With contributions from AGITG members to the SCOT Study and the SCOT data included IDEA meta-analysis these two research projects in colorectal cancer were also presented at ASCO.
Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer. | 2017 ASCO Annual Meeting Abstracts
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status